



| | | | |
|---|--|--|------------|
| FEDERAL HDP-1449 (Based on Form PTO-1449) | | ATTORNEY DOCKET NO. | SERIAL NO. |
| PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITIGATION (Use several sheets if necessary) | | 6239/I/US (31437/USA; 6794-000148/US) | 10/047,902 |
| Sheet 1 of 1 | | APPLICANT | |
| | | Ping Gao, et al. | |
| | | FILING DATE | GROUP |
| | | January 14, 2002 | 1653 |

U.S. PATENT DOCUMENTS

| Ref. Desig. | Examiner's Initials | Document Number | Date | Name | Class/ Subclass | (If appropriate) Filing Date |
|-------------|---------------------|-----------------|------|------|-----------------|------------------------------|
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Ref. Desig. | Examiner's Initials | Document Number | Date | Country | Class/ Subclass | Translation Yes No |
|-------------|---------------------|-----------------|------------|-------------|-----------------|-----------------------|
| 1. | Smur | CH 688 504 A5 | 10/31/1997 | Switzerland | A61K 031/015 | partial |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

| Ref. Desig. | Examiner's Initials | |
|-------------|---------------------|--|
| 2. | Smur | Eiseman et al, <i>Plasma Pharmacokinetics and Tissue Distribution of Paclitaxel in CD₂F₁ Mice</i> , CANCER CHEMOTHER PHARMACO. 34:465-471 (1994) |
| 3. | ↓ | Slater et al, <i>Comparison of Cyclosporin A, Verapamil, PSC-833 and Cremophor EL As Enhancing Agents of VP-16 in Murine Lymphoid Leukemias</i> , LEUKEMIA RESEARCH 19(8):543-548 (1995) |
| 4. | ↓ | Sharma et al, <i>Novel Taxol® Formulation: Polyvinylpyrrolidone Nanoparticle-Encapsulated Taxol® for Drug Delivery in Cancer Therapy</i> , ONCOLOGY RESEARCH 9(7/8):281-286 (1996) |
| 5. | ↓ | International Search Report for International Patent Application No. PCT/US02/00497 |

EV 639015271 US

Examiner: Douglas M. (Mayer) Cookes

Date Considered: 10/18/2005

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.